Impressive Trial Results for Blinatumomab at ASH 2011
Blinatumomab was once again the winner of many plaudits at the American Society of Hematology, its high efficacy being noted once more. Good commentary on Ohad Hammer's blog.
The omens are good (touch wood!!) for a successful (and remunerative) product when all the regulatory hurdles have been jumped. Even before that the SP should sky-rocket.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.